Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study
| Autor: | Moshe E. Gatt, Efrat Luttwak, Svetlana Trestman, Irit Avivi, Tamar Tadmor, Kreiniz Natalia, Noam Benyamini, Eyal Lebel, Noa Lavi, Celia Suriu, Moshe Mittelman, Netanel A. Horowitz, Ory Rouvio, Yael C Cohen, Mika Geva |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Subgroup analysis Ixazomib Bortezomib 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Maintenance therapy Internal medicine medicine Autologous transplantation Humans Adverse effect Multiple myeloma Lenalidomide Aged Retrospective Studies Aged 80 and over business.industry Hematology Middle Aged medicine.disease Treatment Outcome Oncology chemistry 030220 oncology & carcinogenesis Female business Multiple Myeloma 030215 immunology medicine.drug |
| Zdroj: | Clinical lymphoma, myelomaleukemia. 20(11) |
| ISSN: | 2152-2669 |
| Popis: | Background Lenalidomide and ixazomib maintenance improve long-term outcomes in newly diagnosed multiple myeloma (NDMM) patients. However, there is less evidence to support bortezomib (BTZ) maintenance therapy, and real-life data on maintenance are scarce. We investigated the efficacy and safety of BTZ maintenance therapy in NDMM. Patients and Methods A retrospective multisite study was performed in 6 medical centers in Israel. All consecutive patients with NDMM diagnosed between January 1, 2010, and July 3, 2019, who received a BTZ-based induction, with or without an autologous transplantation, followed by BTZ maintenance therapy, were identified. Maintenance therapy was defined as BTZ (1.3 mg/m2) once every 2 weeks, administered subcutaneously alone or with dexamethasone, or weekly BTZ monotherapy. Results A total of 105 patients were identified, 58 of whom had received a transplant (transplant eligible) and 47 who had not (not transplant eligible). During BTZ maintenance therapy, 96% had one or more adverse event, 11.5% had grade 3 or higher adverse events, and 11.5% discontinued treatment due to toxicity. Median progression-free survival (PFS) and overall survival were 45 and 91.5 months, respectively; 4-year survival was 88%. Adverse cytogenetics was associated with worse PFS (24 vs. 46 months, P = .001). In subgroup analysis, adverse cytogenetics were associated with worse PFS (P Conclusion Analysis of multisite real-life data showed that BTZ maintenance therapy is safe, well tolerated, and effective. Median PFS was similar to that reported with alternative maintenance strategies. Our findings further support its use among patients with adverse cytogenetics, it may also be relevant for patients with lenalidomide-intolerant disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect